Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Levorphanol. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 known ✓ | P35372 | 6/20 | 0.98 |
| ▸ | OPRD1 | P41143 | 5/20 | 1.00 |
| ▸ | GRIN1 | Q05586 | 8/20 | 0.98 |
| ▸ | GRIN2A | Q12879 | 8/20 | 0.98 |
| ▸ | GRIN2D | O15399 | 7/20 | 0.98 |
| ▸ | GRIN3B | O60391 | 7/20 | 0.98 |
| ▸ | GRIN2B | Q13224 | 7/20 | 0.98 |
| ▸ | GRIN2C | Q14957 | 7/20 | 0.98 |
| ▸ | GRIN3A | Q8TCU5 | 7/20 | 0.98 |
| ▸ | OPRK1 | P41145 | 5/20 | 0.98 |
| ▸ | SLC22A1 | O15245 | 3/20 | 0.98 |
| ▸ | SLC6A4 | P31645 | 3/20 | 0.98 |
| ▸ | MRGPRX2 | Q96LB1 | 3/20 | 0.98 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.98 |
| ▸ | SLC6A2 | P23975 | 3/20 | 0.98 |
| ▸ | SCN1A | P35498 | 2/20 | 0.98 |
| ▸ | SCN2A | Q99250 | 2/20 | 0.98 |
| ▸ | SCN3A | Q9NY46 | 2/20 | 0.98 |
| ▸ | ADRA2A | P08913 | 2/20 | 0.98 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.98 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Dextrorphan SCHEMBL122564 | 1.00 | OPRD1 (1.00) | OPRD1GRIN1GRIN2AGRIN2DGRIN3B | |
| Levorphanol SCHEMBL32667565 | 1.00 | OPRD1 (1.00) | OPRD1GRIN1GRIN2AGRIN2DGRIN3B | |
| Levorphanol SCHEMBL24335 | 0.99 | GRIN1 (1.00) | OPRD1GRIN1GRIN2AGRIN2DGRIN3B | |
| Levorphanol SCHEMBL3495833 | 0.99 | GRIN1 (1.00) | OPRD1GRIN1GRIN2AGRIN2DGRIN3B | |
| Levorphanol SCHEMBL16310821 | 0.99 | GRIN1 (1.00) | OPRD1GRIN1GRIN2AGRIN2DGRIN3B | |
| Levorphanol SCHEMBL12232844 | 0.99 | GRIN1 (1.00) | OPRD1GRIN1GRIN2AGRIN2DGRIN3B | |
| Levorphanol SCHEMBL21095576 | 0.99 | GRIN1 (1.00) | OPRD1GRIN1GRIN2AGRIN2DGRIN3B | |
| Levorphanol SCHEMBL22722062 | 0.99 | GRIN1 (1.00) | OPRD1GRIN1GRIN2AGRIN2DGRIN3B | |
| Dextrorphan SCHEMBL20535964 | 0.99 | GRIN1 (1.00) | OPRD1GRIN1GRIN2AGRIN2DGRIN3B | |
| Levorphanol SCHEMBL22791693 | 0.99 | GRIN1 (1.00) | OPRD1GRIN1GRIN2AGRIN2DGRIN3B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-4486436-A | Analgesic and anti-inflammatory compositions comprising caffeine and methods of using same | ANALGESIC ASSOCIATES (US) | 1984-12-04 | — | — | US | claimed |
| US-12590065-B2 | Levorphanol prodrugs and processes for making and using them | ZEVRA THERAPEUTICS, INC. (US) | 2026-03-31 | — | — | US | disclosed |
| US-20210002226-A1 | LEVORPHANOL PRODRUGS AND PROCESSES FOR MAKING AND USING THEM | ALTER DOMUS (US) LLC | 2021-01-07 | — | — | US | disclosed |
| EP-3045043-B1 | EXTENDED RELEASE ORAL PHARMACEUTICAL COMPOSITIONS OF 3-HYDROXY-N-METHYLMORPHINAN AND METHOD OF USE | RELMADA THERAPEUTICS INC (US) | 2020-04-29 | — | — | EP | disclosed |
| EP-3045043-A1 | EXTENDED RELEASE ORAL PHARMACEUTICAL COMPOSITIONS OF 3-HYDROXY-N-METHYLMORPHINAN AND METHOD OF USE | Relmada Therapeutics, Inc. (US) | 2016-07-20 | — | — | EP | disclosed |
| EP-2448406-B1 | EXTENDED RELEASE ORAL PHARMACEUTICAL COMPOSITIONS OF 3-HYDROXY-N-METHYLMORPHINAN AND METHOD OF USE | RELMADA THERAPEUTICS INC (US) | 2016-04-20 | — | — | EP | disclosed |
| EP-2448406-A1 | EXTENDED RELEASE ORAL PHARMACEUTICAL COMPOSITIONS OF 3-HYDROXY-N-METHYLMORPHINAN AND METHOD OF USE | Relmada Therapeutics, Inc. (US) | 2012-05-09 | — | — | EP | disclosed |
| US-20120065221-A1 | Extended Release Oral Pharmaceutical Compositions of 3-Hydroxy-N-Methylmorphinan and Method of Use | THERAQUEST BIOSCIENCES, INC. (PA) | 2012-03-15 | — | — | US | disclosed |
| WO-2010099508-A1 | EXTENDED RELEASE ORAL PHARMACEUTICAL COMPOSITIONS OF 3-HYDROXY-N-METHYLMORPHINAN AND METHOD OF USE | THERAQUEST BIOSCIENCES, INC. (US) | 2010-09-02 | — | — | WO | disclosed |
| US-20030069318-A1 | Salts of analgesic substances in oil, and methods of making and using the same | GUILFORD PHARMACEUTICALS, INC. | 2003-04-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12590065-B2 | Levorphanol prodrugs and processes for making and using them | SLC16A3, SLC16A8, SLC16A1 | OPRM1 164/4885OPRD1 192/4885GRIN1 807/4885 |
| US-20210002226-A1 | LEVORPHANOL PRODRUGS AND PROCESSES FOR MAKING AND USING THEM | OPRM1, OPRK1, OPRD1 | OPRM1 1/4885OPRD1 3/4885GRIN1 2031/4885 |
| US-20030069318-A1 | Salts of analgesic substances in oil, and methods of making and using the same | OPRL1, OPRK1, ACHE | OPRM1 8/4885OPRD1 40/4885GRIN1 680/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.